Phase 2 Study of Pracinostat With Azacitidine in Patients With Previously Untreated Myelodysplastic Syndrome
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, double-blind, placebo-controlled study is to determine the
safety and efficacy of pracinostat compared to placebo when combined with azacitidine, and
FDA approved treatment for Myelodysplastic Syndrome (MDS).